Response to 'Before blaming levodopa/carbidopa intestinal gel for demyelinating polyneuropathy, all differential aetiologies must be ruled out'

Neurol Neurochir Pol. 2023;57(4):403-404. doi: 10.5603/PJNNS.a2023.0045. Epub 2023 Jul 19.

Authors

Radosław Piekarski^{1

2}, Anna Roszmann^{3

4}, Jarosław Dulski^{3

4}, Jarosław Sławek^{3

4}

Affiliations

¹ Department of Neurology & Stroke, St. Adalbert Hospital, Gdansk, Poland. [email protected].
² Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland. [email protected].
³ Department of Neurology & Stroke, St. Adalbert Hospital, Gdansk, Poland.
⁴ Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland.

PMID: 37466034
DOI: 10.5603/PJNNS.a2023.0045

No abstract available

Publication types

Comment

MeSH terms

Antiparkinson Agents / adverse effects
Carbidopa / therapeutic use
Drug Combinations
Humans
Levodopa / adverse effects
Parkinson Disease* / drug therapy
Polyneuropathies* / chemically induced

Substances

Levodopa
Carbidopa
Antiparkinson Agents
Drug Combinations